This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

MF is a BCR-ABL1–negative chronic myeloproliferative neoplasm (MPN), a collection of heterogeneous cancers that includes primary MF (PMF) and secondary MF that sometimes forms in patients first diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET). The role of the JAK pathway and its aberrant activation in MF has long been appreciated. Importantly, the treatment armamentarium for MF is expanding with the emergence of new agents targeting the JAK pathway alongside other key regulators of immunity and inflammation. As such, treatment selection for MF is increasingly based on patient preference, with consideration given to treatment-related side effects, symptom burden, and transfusion dependency.

This educational initiative will update the interprofessional care team on current and emerging therapies for the treatment and management of MF, including treatment risks and benefits, barriers to adherence, and side effect monitoring and management. These concepts are coupled with education about shared decision-making strategies and other related approaches to achieve increased patient satisfaction, better adherence to treatment plans, and greater treatment engagement, as well as to enhance quality decision-making.

FDA Approval September 2023: Momelotinib as First- and Second-line Treatment

For the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis …=

This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient’s residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option.

Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient’s residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option.

This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient’s residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option.

Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient’s residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option.

Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all patients receive the care they need.

This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.